During the presentation, Dr. Cobuzzi will discuss Diffusion Pharmaceuticals’ business strategy, which focuses on developing Trans Sodium Crocetinate to treat a variety of diseases driven by hypoxemia.
Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment CHARLOTTESVILLE, Va., Oct. 15, 2018 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback